Whole sections

  • 文章类型: Journal Article
    背景:卵巢透明细胞癌(OCCC),以其对铂类化疗的化学抗性而闻名,在抗PD-1/PD-L1抑制剂的临床试验中表现出良好的反应。通过评估PD-L1表达,我们试图确定PD-1/PD-L1抑制剂在OCCC中的潜在治疗益处.
    结果:回顾性研究包括北京协和医院2019年至2022年间152名OCCC患者。还包括原发性与复发性病变(来自15例患者的17对)或原发性与转移性病变(来自9例患者的11对)的成对肿瘤。22C3pharmDx测定和整个切片用于PD-L1免疫组织化学染色。具有上市前临床试验经验的病理学家根据各种诊断标准(TPS1%,CPS1或CPS10)。PD-L1阳性例数和百分比为34(22.4%,TPS≥1%)和59(38.8%,CPS≥1),分别。33例(21.7%)患者PD-L1高表达(CPS≥10)。一半的铂类耐药患者(11/22)为PD-L1阳性(CPS≥1)。此外,PD-L1阳性表达(CPS≥1)与预后较差的临床病理特征有关,如高级阶段,淋巴结转移,和远处转移(分别为p=0.032,p<0.001和p=0.003)。与匹配的原发病灶相比,PD-L1在复发病灶中表达相等或更多。
    结论:结论:抗PD-1/PD-L1抑制剂是OCCC的有希望的治疗选择.为了评估PD-L1的表达,CPS比TPS更推荐。当无法获得原发肿瘤组织时,对复发病变的评估仍然是合适和可预测的。远处转移性病变可以作为PD-L1评估的替代样本,而不建议使用淋巴转移性病变。
    BACKGROUND: Ovarian clear cell carcinoma (OCCC), well known for its chemoresistance to platinum-based chemotherapy, exhibited a good response in clinical trials of anti-PD-1/PD-L1 inhibitors. By assessing PD-L1 expression, we sought to determine the potential therapeutic benefit of PD-1/PD-L1 inhibitors in OCCC.
    RESULTS: The retrospective study included 152 individuals with OCCC between 2019 and 2022 at Peking Union Medical College Hospital. Paired tumors of primary versus recurrent lesions (17 pairs from 15 patients) or primary versus metastatic lesions (11 pairs from 9 patients) were also included. The 22C3 pharmDx assay and whole sections were used for PD-L1 immunohistochemical staining. Pathologists with experience in premarket clinical trials evaluated PD-L1 expression based on various diagnostic criteria (TPS 1%, CPS 1, or CPS 10). The number and percentage of positive PD-L1 cases were 34 (22.4%, TPS ≥ 1%) and 59 (38.8%, CPS ≥ 1), respectively. Thirty-three (21.7%) of the cases had high PD-L1 expression (CPS ≥ 10). Half of the platinum-resistant patients (11/22) were PD-L1 positive (CPS ≥ 1). In addition, positive PD-L1 expression (CPS ≥ 1) was related to clinicopathological characteristics that represented a worse prognosis, such as advanced stages, lymph node metastasis, and distant metastasis (p = 0.032, p < 0.001 and p = 0.003, separately). PD-L1 was expressed equally or more in the recurrent lesion compared with its matched primary lesion.
    CONCLUSIONS: In conclusion, anti-PD-1/PD-L1 inhibitors are a promising therapeutic choice for OCCC. For evaluation of PD-L1 expression, CPS is more recommended than TPS. Evaluation of recurrent lesion was still suitable and predictive when the primary tumor tissue was not available. Distant metastatic lesions can serve as alternative samples for PD-L1 evaluation, while usage of lymphatic metastatic lesions is not recommended.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Evaluation Study
    整个切片对于原位研究细胞形态的发育和谷粒中贮藏物质的积累很重要。我们开发了一种改进的,在中期和后期(花后28天和35天)籽粒灌浆过程中获得优质小麦籽粒完整组织学切片的简单方法。小麦籽粒被固定和脱水,在氯仿中清除3天,并在55°C下在石蜡中渗透3-5天。然后将渗入的颗粒包埋在石蜡中,切片前使用焦碳酸二乙酯(DEPC)水软化。经过这些治疗,小麦籽粒可以在10-25μm处容易地切片,同时保持细胞结构和抗原性。细胞结构,细胞分布,自发荧光,很容易观察到bam1的淀粉积累和原位定位,bam1是编码晚期小麦籽粒切片中β-淀粉酶转录本的基因之一。
    Whole sections are important for investigation in situ of the development of cell morphology and accumulation of storage substance in cereal kernels. We developed an improved, simple method to obtain good quality whole histological sections of wheat grains during mid- and late-stage (28 and 35 days post anthesis) grain filling. The wheat grains were fixed and dehydrated, cleared in chloroform for 3 days and infiltrated in paraffin at 55° C for 3 - 5 days. The infiltrated grains then were embedded in paraffin wax, softened using diethyl pyrocarbonate (DEPC) water before sectioning. After these treatments, the wheat grains can be sectioned easily at 10 - 25 μm while retaining the cellular structure and antigenicity. The cell structure, cell distribution, autofluorescence, starch accumulation and localization in situ of bam1, one of the genes encoding β-amylase transcripts in the sections of the late developing wheat grain were observed readily.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号